Keywords: xenova, performing, line, expectations, 1st, qtr, increased
Xenova Performing In Line With Expectations In 1st Qtr
Article | 19 May 1997
Increased clinical trial and drug development activities at the UK-basedemerging pharmaceutical group, Xenova, were behind a 61.8% rise in operating expenses ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
